Amgen Inc. Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax
Amgen Inc. (AMGN) reported Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax of $110.00 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-09.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax · last filed 2021-02-09
- Amgen Inc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2020 was $110.00M, a 139.13% increase from fiscal 2019.
- Amgen Inc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2019 was $46.00M.
- Amgen Inc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2018 was -$55.00M.
- Amgen Inc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2017 was -$226.00M, a 591.30% decline from fiscal 2016.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 12 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 12 month as first filed |
|---|---|---|
| 2020-12-31 | $110.00M 10-K · filed 2021-02-09 | |
| 2019-12-31 | $46.00M 10-K · filed 2021-02-09 | -$46.00M 10-K · filed 2020-02-12 |
| 2018-12-31 | -$55.00M 10-K · filed 2021-02-09 | $55.00M 10-K · filed 2019-02-13 |
| 2017-12-31 | -$226.00M 10-K · filed 2020-02-12 | |
| 2016-12-31 | $46.00M 10-K · filed 2019-02-13 | |
| 2015-12-31 | -$53.00M 10-K · filed 2018-02-13 | $53.00M 10-K · filed 2016-02-16 |
| 2014-12-31 | $74.00M 10-K · filed 2017-02-14 | -$74.00M 10-K · filed 2015-02-19 |
| 2013-12-31 | $33.00M 8-K · filed 2016-10-31 | -$33.00M 10-K · filed 2014-02-24 |
| 2012-12-31 | $49.00M 10-K · filed 2015-02-19 | -$49.00M 10-K · filed 2014-02-24 |
| 2011-12-31 | $41.00M 10-K · filed 2014-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |